5 years ago

F2G Secures $60.8 Million in Funding for Antifungal Therapies

  • F2G, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, secured US $60.8 million in new financing

  • New global institutional investor Cowen Healthcare Investments joined the round

  • Existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences also participated

  • Proceeds from the financing will be used to fund F2G’s late-stage clinical programs for Olorofim, its novel antifungal agent and organisational scale-up in preparation for commercialisation.

      • ProblemHealthcare

      "Millions of people around the world suffer from life-threatening fungal infections, with limited treatment options, especially for rare and resistant strains."

      Solution

      "F2G is developing Olorofim, a novel antifungal agent that targets dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway, offering a new and potentially more effective treatment for these infections."

      Covered on